SEC Comment Letter for U S PHYSICAL THERAPY (USPH) — Sep 8, 2021
U S PHYSICAL THERAPY INC /NV (USPH) (CIK 0000885978)
Date: Sept. 8, 2021 · CIK: 0000885978 · Accession: 0000000000-21-010907
AI Filing Summary & Sentiment
File numbers found in text: 001-11151
Referenced dates: August 10, 2021
Show Raw Text
United States securities and exchange commission logo
September 8, 2021
Carey Hendrickson
Chief Financial Officer
U.S. Physical Therapy, Inc.
1300 West Sam Houston Parkway South, Suite 300
Houston, TX 77042
Re:U.S. Physical Therapy, Inc.
Form 10-K For The Fiscal Year Ended December 31, 2020
Filed March 1, 2021
Response Dated August 19, 2021
File No. 001-11151
Dear Mr. Hendrickson:
We have reviewed your August 19, 2021 response to our comment letter and have the
following comment. In our comment, we may ask you to provide us with information so we may
better understand your disclosure.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Form 10-K For The Fiscal Year Ended December 31, 2020
Item 6. Management's Discussion and Analysis of Financial Condition and Results of Operations
Results of Operations, Fiscal Year 2020 Compared to Fiscal 2019 , page 31
1.We reference your response to prior comment 1 in our letter dated August 10, 2021.
Please also revise future filings to clearly label "Gross profit, excluding closure costs" and
"Operating costs, excluding closure costs" as non-GAAP within the table reconciling the
above mentioned non-GAAP measures to the related GAAP measures. We reference the
example of the format you have provided in your response.
FirstName LastNameCarey Hendrickson
Comapany NameU.S. Physical Therapy, Inc.
September 8, 2021 Page 2
FirstName LastName
Carey Hendrickson
U.S. Physical Therapy, Inc.
September 8, 2021
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
You may contact Kristin Lochhead at (202) 551-3664 or Brian Cascio, Accounting
Branch Chief, at (202) 551-3676 if you have any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences